We are primarily interested in technology development with a view to generation of biologics (peptides and miniproteins) targeting dysfunctional p53 pathway components. In particular, we develop and employ a range of directed evolution methodologies for protein engineering and selection. These approaches are also being used to engineer/re-purpose enzymes for industrially relevant applications, with current focus on development of “greener” enzyme alternatives for pharmaceutical synthesis. A further area of interest is development of novel biosensing platforms, with emphasis on modular protein biosensors for facile drug screening and diagnostic applications.
Farid J. Ghadessy - Group Leader
Siau Jia Wei
Chee Min Qi Sharon
Lau Sze Yi
Lim Ting Xiang
- Development and structural characterization of an engineered multi-copper oxidase reporter of protein-protein interactions. Sana B, Chee SMQ, Wongsantichon J, Raghavan S, Robinson RC, Ghadessy FJ. J Biol Chem. 2019 Feb 15.
- Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function.Lau SY, Siau JW, Sobota RM, Wang CI, Zhong P, Lane DP, Ghadessy FJ. Protein Eng Des Sel. 2018 Jul 1;31(7-8):301-312.
- Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids. Chee SMQ, Wongsantichon J, Siau J, Thean D, Ferrer F, Robinson RC, Lane DP, Brown CJ, Ghadessy FJ. PLoS One. 2017 Dec 11;12(12).
- Development of a genetically programed vanillin-sensing bacterium for high-throughput screening of lignin-degrading enzyme libraries. Sana B, Chia KHB, Raghavan SS, Ramalingam B, Nagarajan N, Seayad J, Ghadessy FJ. Biotechnol Biofuels. 2017 Feb 3;10:32.